LV10191B - Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv) - Google Patents

Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv) Download PDF

Info

Publication number
LV10191B
LV10191B LVP-93-231A LV930231A LV10191B LV 10191 B LV10191 B LV 10191B LV 930231 A LV930231 A LV 930231A LV 10191 B LV10191 B LV 10191B
Authority
LV
Latvia
Prior art keywords
fiau
metabolite
hepatitis
patients
predecessor
Prior art date
Application number
LVP-93-231A
Other languages
English (en)
Latvian (lv)
Other versions
LV10191A (lv
Inventor
Dennis W Adair
Kenneth A Smiles
Original Assignee
Oclassen Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oclassen Pharma Inc filed Critical Oclassen Pharma Inc
Publication of LV10191A publication Critical patent/LV10191A/xx
Publication of LV10191B publication Critical patent/LV10191B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LVP-93-231A 1992-04-06 1993-04-06 Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv) LV10191B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86389092A 1992-04-06 1992-04-06
US95292792A 1992-09-25 1992-09-25
US07/959,004 US5432165A (en) 1992-04-06 1992-10-09 Methods for the treatment of infection caused by Hepatitis B virus (HBV)

Publications (2)

Publication Number Publication Date
LV10191A LV10191A (lv) 1994-10-20
LV10191B true LV10191B (en) 1995-04-20

Family

ID=27420427

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-231A LV10191B (en) 1992-04-06 1993-04-06 Compositions for the treatment of infection and disease caused by hepatitis b virus (hbv)

Country Status (26)

Country Link
US (1) US5432165A (es)
EP (1) EP0565412A1 (es)
JP (1) JPH069403A (es)
CN (1) CN1081879A (es)
AP (1) AP372A (es)
AU (1) AU662804B2 (es)
BE (1) BE1009181A5 (es)
BR (1) BR9306207A (es)
CA (1) CA2092356A1 (es)
EE (1) EE9400068A (es)
ES (1) ES2105923B1 (es)
FR (1) FR2689398B1 (es)
GR (1) GR930100111A (es)
IL (1) IL105169A0 (es)
IT (1) IT1264332B1 (es)
LV (1) LV10191B (es)
MD (1) MD940152A (es)
MX (1) MX9301922A (es)
NO (1) NO931246L (es)
NZ (1) NZ247188A (es)
OA (1) OA10102A (es)
PH (1) PH31116A (es)
PT (1) PT101238A (es)
SI (1) SI9300144A (es)
WO (1) WO1993019762A1 (es)
YU (1) YU23993A (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996010649A1 (en) * 1994-09-30 1996-04-11 Southwest Foundation For Biomedical Research Isolated human hepatitis b virus polymerase and uses thereof
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6296882B1 (en) * 2000-06-12 2001-10-02 Manuel Viamonte, Jr. Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, and lemon oil
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
EP2427213B1 (en) * 2009-05-08 2015-04-01 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (es) *
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds

Also Published As

Publication number Publication date
MD940152A (ro) 1995-12-31
LV10191A (lv) 1994-10-20
EP0565412A1 (en) 1993-10-13
IT1264332B1 (it) 1996-09-23
MX9301922A (es) 1993-10-01
NO931246L (no) 1993-10-07
AU3530293A (en) 1993-10-07
FR2689398B1 (fr) 1994-11-18
OA10102A (en) 1996-12-18
CN1081879A (zh) 1994-02-16
EE9400068A (et) 1995-12-15
SI9300144A (en) 1994-03-31
WO1993019762A1 (en) 1993-10-14
FR2689398A1 (fr) 1993-10-08
BE1009181A5 (fr) 1996-12-03
YU23993A (sh) 1997-05-28
AP9300513A0 (en) 1993-04-30
AU662804B2 (en) 1995-09-14
PT101238A (pt) 1994-03-31
CA2092356A1 (en) 1993-10-07
AP372A (en) 1994-11-24
ES2105923A1 (es) 1997-10-16
ITTO930226A0 (it) 1993-04-05
NO931246D0 (no) 1993-03-31
GR930100111A (el) 1993-12-30
ITTO930226A1 (it) 1994-10-05
PH31116A (en) 1998-02-28
ES2105923B1 (es) 1998-07-01
IL105169A0 (en) 1993-07-08
US5432165A (en) 1995-07-11
JPH069403A (ja) 1994-01-18
NZ247188A (en) 1995-05-26
BR9306207A (pt) 1998-06-23

Similar Documents

Publication Publication Date Title
US4879277A (en) Antiviral compositions and methods
DE60018273T2 (de) Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv-therapie
EA000626B1 (ru) Синергические комбинации зидовудина, 1592u89 и зтс или ftc
AP372A (en) Compositions containining fialurdine, for the treatment of infection and disease caused by hepatitis B virus (HBV).
CN101466392A (zh) 用于预防或治疗hiv感染的药用组合物及其应用
AU2024264495A1 (en) Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
US5254539A (en) Method of treating HIV with 2',3'-dideoxyinosine
AU755633B2 (en) Antiviral combinations
US6432966B2 (en) Antiviral combinations
EP0243192B1 (en) Antiviral 8-phenylxanthines
EP0979650A1 (en) Antiviral agents
US6040298A (en) Methods for treatment with compositions effective against acyclovir-resistant strains of herpes viruses
EP0290817A2 (en) A Use of oxetanocin for inhibiting HIV
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
WO2009084732A1 (ja) インターフェロン・リバビリン併用療法における副作用軽減剤
COHEN et al. Sprue refractory to vitamin B12; satisfactory response to folic acid
WO2000016754A2 (en) Antiviral combinations comprising lamivudine and lobucavir
Barreiro et al. Tolerance of didanosine as enteric-coated capsules versus buffered tablets
JPH08208502A (ja) 抗エイズウイルス剤の効果増強剤
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
Angus Antiviral drugs
WO2000018383A2 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
HK1035670B (en) Antiviral combinations of lamivudine and adefovir
US20040044016A1 (en) Antiviral agents
JPH1045598A (ja) ウイルス感染症予防治療剤